Stockscreener 앱 받기
130.71
0.66%
0.86
시장 영업 전:
129.22
-1.49
-1.14%
전일 마감가:
$129.85
열려 있는:
$130.14
하루 거래량:
632.37K
Relative Volume:
0.57
시가총액:
$13.12B
수익:
$2.86B
순이익/손실:
$478.60M
주가수익비율:
28.00
EPS:
4.6676
순현금흐름:
$748.70M
1주 성능:
+0.65%
1개월 성능:
+2.31%
6개월 성능:
-8.42%
1년 성능:
+17.23%
1일 변동 폭
$129.88
$131.69
1주일 범위
$127.15
$131.89
52주 변동 폭
$84.23
$160.18
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
130.71 | 13.03B | 2.86B | 478.60M | 748.70M | 4.6676 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.39 | 57.56B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
121.68 | 49.87B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.60 | 46.59B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.09 | 34.31B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
540.02 | 23.42B | 3.18B | 1.33B | 1.04B | 27.90 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Neurocrine at Stifel CNS Forum: Growth and Strategic Focus - Investing.com
Transcript : Neurocrine Biosciences, Inc. Presents at Stifel 2026 Virtual CNS Forum, Mar-17-2026 04 - marketscreener.com
Neurocrine Biosciences (NBIX) CTO Ratz reports initial stock and option grants - Stock Titan
Neurocrine Biosciences promotes Andrew Ratz to operations chief - Investing.com
Neurocrine Biosciences promotes Andrew Ratz to chief technical operations officer - StreetInsider
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer - PR Newswire
Neurocrine Biosciences: The Song Remains The Same (NASDAQ:NBIX) - Seeking Alpha
Iron Triangle Partners LP Acquires New Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Distillate Capital Partners LLC Trims Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Boone Capital Management Decreases Stake in Neurocrine Biosciences - National Today
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Braidwell LP - MarketBeat
Boone Capital Management LLC Has $23.36 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Assessing Neurocrine Biosciences (NBIX) Valuation After GARP Recognition And Reaffirmed Confidence In Ingrezza - simplywall.st
Dodge & Cox Decreases Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
2Xideas AG Trims Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Swiss National Bank Sells 14,100 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top GARP Pick with Strong Growth and a Reasonable Price - ChartMill
Connor Clark & Lunn Investment Management Ltd. Acquires 32,480 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Given New $177.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Neurology stocks rebound in 2025 after midyear slump - bioworld.com
Magnetar Financial LLC Acquires New Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Korea Investment CORP Has $10.06 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
First Trust Advisors LP Has $50.97 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Capital Fund Management S.A. Has $17.37 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Is It Time To Reassess Neurocrine Biosciences (NBIX) After The Recent Share Price Pullback - simplywall.st
A Look At Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Pullback - Yahoo Finance
Victory Capital Management Inc. Buys 31,981 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Cantor Fitzgerald Keeps Overweight on NBIX Neurocrine Biosciences March 2026 - Meyka
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum - ChartMill
Cantor Fitzgerald raises Neurocrine Bio price target on Ingrezza outlook By Investing.com - Investing.com Canada
Barclays Increases Stake in Neurocrine Biosciences - National Today
Neurocrine Biosciences, Inc. $NBIX Shares Bought by Barclays PLC - MarketBeat
American Century Companies Inc. Sells 52,349 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Transcript : Neurocrine Biosciences, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 08 - marketscreener.com
The Technical Signals Behind (NBIX) That Institutions Follow - Stock Traders Daily
Rhenman & Partners Asset Management Trims Neurocrine Biosciences Stake - National Today
Rhenman & Partners Asset Management AB Sells 34,500 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
14,653 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Munich Reinsurance Co Stock Corp in Munich - MarketBeat
What insider trading reveals about Neurocrine Biosciences Inc. stockM&A Rumor & Reliable Entry Point Alerts - Naître et grandir
Equifax Expands Data Solutions While Neurocrine Biosciences Advances Neurological Treatment Research - geneonline.com
Two stocks flagged for study: Equifax and Neurocrine Bio review - Stock Titan
Focus Partners Advisor Solutions LLC Buys 8,011 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) CFO discloses bona fide gift of shares - Stock Titan
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Teachers Retirement System of The State of Kentucky - MarketBeat
GW&K Investment Management Trims Neurocrine Biosciences Stake - National Today
GW&K Investment Management LLC Sells 17,980 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Segall Bryant & Hamill LLC - MarketBeat
Neurocrine Biosciences Forms Death Cross, Signaling Potential Bearish Trend - Markets Mojo
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Strong Buy Ratings and 33.92% Potential Upside - DirectorsTalk Interviews
Neurocrine Biosciences, Inc. $NBIX Stock Position Lowered by TD Asset Management Inc - MarketBeat
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
7.61%
자본화:
|
볼륨(24시간):